Dr Reddy's prevê recuperação com o lançamento da semaglutida

A Dr Reddy's Laboratories espera uma recuperação gradual no atual ano fiscal após uma queda nos lucros no ano passado. O crescimento na Índia, na Europa e em mercados emergentes está compensando as pressões nos negócios dos EUA. O lançamento de novos produtos e melhorias nas margens deverão sustentar a expansão.

A empresa registrou uma queda no lucro líquido no ano fiscal anterior, principalmente devido a desafios em suas operações nos EUA. Em contrapartida, os negócios na Índia, na Europa e em mercados emergentes demonstraram um ritmo de crescimento saudável. Os executivos destacaram que essas regiões continuam a apresentar um bom desempenho em meio aos esforços mais amplos de recuperação.

Artigos relacionados

Elderly woman with type 2 diabetes walking healthily outdoors, holding semaglutide pen, with subtle ENDO 2026 study charts in background
Imagem gerada por IA

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

Reportado por IA Imagem gerada por IA Verificado

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Reportado por IA

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.

Reportado por IA

Market expert Sunil Subramaniam has advised caution for investors amid geopolitical uncertainty and rising input costs. He highlighted consumer durables, capital goods and public sector banks as preferred sectors.

Following its 2025 results showing a 45.4% profit drop due to agribusiness delinquency, Banco do Brasil executives at the BB Day event forecast a 'W'-shaped recovery for the sector in 2026. The payments index is expected to reach 95%, with delinquency pressuring results into mid-year amid risks like Middle East tensions and El Niño. The bank will maintain risk-calibrated lending with stronger guarantees.

Reportado por IA

India's FMCG sector has posted a subdued performance in 2026, with the index down 10 percent year to date. Several leading companies have recorded double-digit declines amid geopolitical tensions and inflation.

quarta-feira, 24 de junho de 2026, 01:25h

Largecaps lead profit growth in March 2026 quarter

sexta-feira, 05 de junho de 2026, 17:38h

India posts 7.8 percent GDP growth in March quarter

sábado, 23 de maio de 2026, 10:29h

Gokaldas Exports reports 9% sequential rise in Q4 revenue

quarta-feira, 20 de maio de 2026, 21:30h

GoodRx upgraded to neutral rating after earnings

quarta-feira, 20 de maio de 2026, 15:49h

Gland Pharma shares hit 52-week high after results

sexta-feira, 15 de maio de 2026, 16:51h

UnitedHealth reports strong first quarter at healthcare conference

sexta-feira, 15 de maio de 2026, 02:19h

ARS Pharmaceuticals reports strong start to 2026 in earnings call

quinta-feira, 14 de maio de 2026, 14:14h

Dexcom outlines growth plans at 2026 investor day

segunda-feira, 11 de maio de 2026, 05:18h

Hims & Hers reports mixed first quarter results

quinta-feira, 23 de abril de 2026, 19:43h

SAP reports strong cloud growth in first quarter

 

 

 

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar